Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Amarin remains undervalued under almost any scenario, says Cowen » 07:51
01/22/21
01/22
07:51
01/22/21
07:51
AMRN

Amarin

$6.31 /

+0.11 (+1.78%)

Cowen analyst Ken…

Cowen analyst Ken Cacciatore believes Amarin shares remain undervalued remain undervalued under almost any scenario and said its valuation appears too discounted. He believes the company's best path forward it to cease US promotional spending to maximize profitability and then sell the company for European value, Cacciatore maintained his Outperform rating and $10 price target on Amarin shares.

ShowHide Related Items >><<
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
12/14/20 Piper Sandler
Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

Yesterday
On The Fly
Fly Intel: After-Hours Movers » 18:35
01/21/21
01/21
18:35
01/21/21
18:35
SIVB

SVB Financial

$455.02 /

-7.49 (-1.62%)

, WAL

Western Alliance

$69.40 /

-1.92 (-2.69%)

, INDB

Independent Bank

$78.68 /

-1.39 (-1.74%)

, OZK

Bank OZK

$34.03 /

-0.59 (-1.70%)

, FLDM

Fluidigm

$6.17 /

+0.31 (+5.29%)

, MNOV

MediciNova

$5.78 /

+0.09 (+1.58%)

, SWIR

Sierra Wireless

$18.41 /

+0.02 (+0.11%)

, ALDX

Aldeyra

$11.77 /

-0.48 (-3.92%)

, AMRN

Amarin

$6.31 /

+0.11 (+1.78%)

, IBM

IBM

$131.80 /

+1.72 (+1.32%)

, STX

Seagate

$63.00 /

+1.57 (+2.56%)

, PPG

PPG

$143.94 /

-0.635 (-0.44%)

, ISRG

Intuitive Surgical

$799.43 /

-0.18 (-0.02%)

, CSX

CSX

$91.61 /

-1.6101 (-1.73%)

, PGEN

Precigen

$9.18 /

-0.22 (-2.34%)

, ACB

Aurora Cannabis

$11.17 /

-0.39 (-3.37%)

, F

Ford

$11.53 /

+0.665 (+6.12%)

Check out this evening's…

ShowHide Related Items >><<
SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

01/08/21 Oppenheimer
Oppenheimer calls SVB Financial acquisition of Boston Private a 'good move'
01/05/21 DA Davidson
SVB Financial price target raised to $400 from $365 at DA Davidson
01/05/21 Raymond James
SVB Financial price target raised to $440 from $325 at Raymond James
01/05/21 RBC Capital
SVB Financial price target raised to $437 from $320 at RBC Capital
WAL Western Alliance
$69.40 /

-1.92 (-2.69%)

01/08/21 UBS
Western Alliance upgraded to Buy from Neutral at UBS
01/04/21 Stephens
Brinker, LiveRamp and Vonage among 2021 best ideas at Stephens
12/15/20 Truist
Truist raises price targets on select regional banks
11/04/20 Stephens
Western Alliance resumed with an Overweight at Stephens
INDB Independent Bank
$78.68 /

-1.39 (-1.74%)

12/17/20 Seaport Global
Seaport Global rolls out coverage of Regional and Community Banks with 4 Buys
12/17/20 Seaport Global
Independent Bank initiated with a Neutral at Seaport Global
10/26/20 Compass Point
Independent Bank upgraded to Buy from Neutral at Compass Point
06/24/20 Piper Sandler
Independent Bank downgraded to Neutral from Overweight at Piper Sandler
OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

06/17/20 Raymond James
Bank OZK upgraded to Outperform from Market Perform at Raymond James
06/17/20 Citi
Bank OZK downgraded to Neutral from Buy at Citi
06/17/20 Raymond James
Bank OZK upgraded to Outperform from Market Perform at Raymond James
04/28/20 Truist
Bank OZK price target raised to $22 from $19 at SunTrust
FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
10/19/20 Piper Sandler
Fluidigm test pact in Texas 'another validation,' says Piper Sandler
09/29/20 Piper Sandler
Piper Sandler would be buyers of Fluidigm given recent pullback
MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

01/14/21
Fly Intel: Top five analyst initiations
01/14/21 B. Riley Securities
Sierra Wireless initiated with a Buy at B. Riley Securities
11/25/20 Colliers
Sierra Wireless initiated with a Buy at Colliers
02/14/20 Roth Capital
Roth Capital sees upside in Sierra Wireless after 2020 transition year
ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

01/08/21 Jefferies
Aldeyra could double if topline of TRANQUILITY study positive, says Jefferies
01/08/21 Citi
Aldeyra shares have 'plenty of upside' despite 26% rally, says Citi
01/07/21 Alliance Global Partners
Aldeyra in an 'enviable position' after Phase 3 Tranquility data, says AGP
12/16/20 Berenberg
Berenberg starts Aldeyra with Buy, sees near-term catalysts
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
12/14/20 Piper Sandler
Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
IBM IBM
$131.80 /

+1.72 (+1.32%)

10/20/20 Morgan Stanley
Morgan Stanley continues to view IBM as 'a 2022 stock'
10/20/20 Citi
IBM is 'getting even more complex,' says Citi
10/20/20 BMO Capital
IBM price target lowered to $138 from $140 at BMO Capital
10/09/20 Morgan Stanley
IBM price target raised to $140 from $128 at Morgan Stanley
STX Seagate
$63.00 /

+1.57 (+2.56%)

01/21/21 Barclays
Seagate price target raised to $60 from $41 at Barclays
01/20/21 Wedbush
Seagate price target raised to $56 from $47 at Wedbush
01/19/21 Northland
Seagate price target raised to $72 from $65 at Northland
01/19/21 Loop Capital
Seagate price target raised to $70 from $60 at Loop Capital
PPG PPG
$143.94 /

-0.635 (-0.44%)

01/20/21 Citi
Citi adds PPG to US Focus List, removes FMC
01/14/21 Berenberg
PPG upgraded to Buy with $165 price target at Berenberg
01/14/21 Berenberg
PPG upgraded to Buy from Hold at Berenberg
12/01/20 Deutsche Bank
PPG price target raised to $165 from $155 at Deutsche Bank
ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight on valuation at Morgan Stanley
12/15/20 Morgan Stanley
Intuitive Surgical downgraded to Equal Weight from Overweight at Morgan Stanley
11/24/20 Raymond James
Intuitive Surgical not surprised by J&J robot features, says Raymond James
10/16/20 JPMorgan
Intuitive Surgical price target raised to $785 from $765 at JPMorgan
CSX CSX
$91.61 /

-1.6101 (-1.73%)

01/20/21 Susquehanna
Railroad recovery expected to continue in 2021, says Susquehanna
01/11/21 Citi
CSX price target raised to $105 from $87 at Citi
12/10/20 Morgan Stanley
Morgan Stanley downgrades CSX to Underweight with bar raised too high
12/10/20 Morgan Stanley
CSX downgraded to Underweight from Equal Weight at Morgan Stanley
PGEN Precigen
$9.18 /

-0.22 (-2.34%)

12/16/20 H.C. Wainwright
Precigen price target raised to $10 from $8 at H.C. Wainwright
05/08/20
Fly Intel: Top analyst initiations
05/08/20 H.C. Wainwright
Precigen initiated with a Buy at H.C. Wainwright
ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

01/06/21 BMO Capital
Federal cannabis reform in U.S. likely to take time, says BMO Capital
12/17/20 BMO Capital
Aurora Cannabis downgraded to Underperform from Market Perform at BMO Capital
12/04/20 Alliance Global Partners
Alliance Global sees low odds of MORE Act passing this congressional session
12/02/20 Alliance Global Partners
Alliance Global Partners sees UN cannabis reclassification helping legalization
F Ford
$11.53 /

+0.665 (+6.12%)

01/20/21 Deutsche Bank
Ford price target raised to $11 from $9 at Deutsche Bank
01/20/21 Deutsche Bank
Ford named 'Catalyst Call: Buy Idea' at Deutsche Bank
01/05/21 Benchmark
GM, Roku, Marcus among Benchmark's Best Ideas for first half of 2021
12/23/20 Morgan Stanley
Apple's potential EV entry represents 'new Tesla bear case,' says Morgan Stanley
WAL Western Alliance
$69.40 /

-1.92 (-2.69%)

SWIR Sierra Wireless
$18.41 /

+0.02 (+0.11%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

OZK Bank OZK
$34.03 /

-0.59 (-1.70%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

INDB Independent Bank
$78.68 /

-1.39 (-1.74%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ALDX Aldeyra
$11.77 /

-0.48 (-3.92%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

  • 22
    Jan
  • 22
    Jan
  • 14
    Jan
  • 11
    Nov
IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

SIVB SVB Financial
$455.02 /

-7.49 (-1.62%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

STX Seagate
$63.00 /

+1.57 (+2.56%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

PGEN Precigen
$9.18 /

-0.22 (-2.34%)

MNOV MediciNova
$5.78 /

+0.09 (+1.58%)

ISRG Intuitive Surgical
$799.43 /

-0.18 (-0.02%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FLDM Fluidigm
$6.17 /

+0.31 (+5.29%)

F Ford
$11.53 /

+0.665 (+6.12%)

CSX CSX
$91.61 /

-1.6101 (-1.73%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

ACB Aurora Cannabis
$11.17 /

-0.39 (-3.37%)

Hot Stocks
Amarin announces CSC included icosapent ethyl in CD prevention guidelines » 18:27
01/21/21
01/21
18:27
01/21/21
18:27
AMRN

Amarin

$6.31 /

+0.11 (+1.78%)

The company states:…

The company states: "Amarin announced that the Chinese Society of Cardiology, or CSC, has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include "icosapent ethyl grams twice a day as a treatment consideration to further lower atherosclerotic cardiovascular disease (ASCVD) in the appropriate patient population. In November 2020, Amarin shared positive, statistically significant top-line results from a Phase 3 clinical trial of VASCEPA conducted in China by Amarin's partner, Edding. The study, which investigated VASCEPA as a treatment for patients with very high triglycerides (greater than or equal to500 mg/dL), met its primary efficacy endpoint and demonstrated a safety profile similar to placebo. This pivotal study mirrored Amarin's MARINE study in patients from the United States and other countries and showed consistency across the Chinese and non-Chinese study populations. These findings will provide support as Edding progresses towards and through the next steps of regulatory submission and review of VASCEPA for potential approval in Mainland China. The CSC recommendation is classified as a Category IIa recommendation denoting that icosapent ethyl is useful and effective and should be considered for treatment of at-risk patients. The classification is an Evidence Level B recommendation which reflects that the evidence comes from a single randomized trial or multiple large non-randomized studies. CSC cited that its recommendations are supported by the results of the REDUCE-IT cardiovascular outcomes study. The CSC does not provide endorsements of any brand name commercial product. Accordingly, CSC Guidelines for Primary Prevention of Cardiovascular Diseases reference icosapent ethyl. The CSC guideline does not reference VASCEPA, the brand name of icosapent ethyl in the United States, and such guideline should not be construed as an endorsement or approval by the CSC of VASCEPA."

ShowHide Related Items >><<
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

01/08/21 Piper Sandler
Piper sees 're-birth' for Amarin shares in 2021, keeps $19 price target
12/28/20 Cantor Fitzgerald
Vascepa showing positive year-over-year trends, says Cantor Fitzgerald
12/23/20 Goldman Sachs
Amarin price target lowered to $6 from $8 at Goldman Sachs
12/14/20 Piper Sandler
Amarin's Vascepa showed 'encouraging results' in Covid patients, says Piper
AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

AMRN Amarin
$6.31 /

+0.11 (+1.78%)

On The Fly
FuboTV jumps as Barrington says buy, Einhorn highlights gains » 13:48
01/21/21
01/21
13:48
01/21/21
13:48
FUBO

FuboTV

$34.78 /

+4.66 (+15.47%)

, REZI

Resideo

$25.01 /

-0.63 (-2.46%)

, DNMR

Danimer Scientific

$38.84 /

+4.49 (+13.07%)

, NCR

NCR Corp.

$33.85 /

-0.16 (-0.47%)

, CHNG

Change Healthcare

$24.05 /

+ (+0.00%)

Shares of FuboTV (FUBO)…

ShowHide Related Items >><<
REZI Resideo
$25.01 /

-0.63 (-2.46%)

NCR NCR Corp.
$33.85 /

-0.16 (-0.47%)

FUBO FuboTV
$34.78 /

+4.66 (+15.47%)

DNMR Danimer Scientific
$38.84 /

+4.49 (+13.07%)

CHNG Change Healthcare
$24.05 /

+ (+0.00%)

FUBO FuboTV
$34.78 /

+4.66 (+15.47%)

01/21/21 Barrington
FuboTV initiated with an Outperform at Barrington
01/19/21 LightShed Partners
FuboTV price target lowered to $6.50 from $8 at LightShed Partners
01/12/21 Roth Capital
FuboTV 'adds another piece to gaming puzzle' with deal, says Roth Capital
01/12/21 Wedbush
Wedbush 'not banking on' FuboTV's 'interesting' sports betting opportunity yet
REZI Resideo
$25.01 /

-0.63 (-2.46%)

12/21/20 JPMorgan
Resideo initiated with an Overweight at JPMorgan
12/14/20 Evercore ISI
Resideo initiated with an Outperform at Evercore ISI
11/06/20 Roth Capital
Resideo upgraded to Buy from Neutral at Roth Capital
08/12/20 Imperial Capital
Resideo upgraded to Outperform from In-Line at Imperial Capital
DNMR Danimer Scientific
$38.84 /

+4.49 (+13.07%)

01/06/21 Jefferies
Danimer Scientific initiated with a Buy at Jefferies
NCR NCR Corp.
$33.85 /

-0.16 (-0.47%)

01/11/21 Wells Fargo
Wells Fargo not ruling out counter-bid for Cardtronics slightly higher than $39
01/11/21 JPMorgan
NCR bid for Cardtronics makes sense, says JPMorgan
01/11/21 Stephens
NCR Corp. price target raised to $49 from $39 at Stephens
12/14/20 Craig-Hallum
Par Technology price target raised to $75 from $55 at Craig-Hallum
CHNG Change Healthcare
$24.05 /

+ (+0.00%)

01/11/21 Berenberg
Change Healthcare downgraded to Hold from Buy at Berenberg
01/07/21 Deutsche Bank
Change Healthcare downgraded to Hold from Buy at Deutsche Bank
01/07/21 Cantor Fitzgerald
Change Healthcare downgraded to Neutral from Overweight at Cantor Fitzgerald
01/07/21 Wells Fargo
Change Healthcare downgraded to Equal Weight from Overweight at Wells Fargo
REZI Resideo
$25.01 /

-0.63 (-2.46%)

NCR NCR Corp.
$33.85 /

-0.16 (-0.47%)

FUBO FuboTV
$34.78 /

+4.66 (+15.47%)

CHNG Change Healthcare
$24.05 /

+ (+0.00%)

  • 30
    Dec
  • 18
    Nov
  • 08
    Oct
  • 07
    Aug
NCR NCR Corp.
$33.85 /

-0.16 (-0.47%)

REZI Resideo
$25.01 /

-0.63 (-2.46%)

NCR NCR Corp.
$33.85 /

-0.16 (-0.47%)

FUBO FuboTV
$34.78 /

+4.66 (+15.47%)

DNMR Danimer Scientific
$38.84 /

+4.49 (+13.07%)

CHNG Change Healthcare
$24.05 /

+ (+0.00%)

FUBO FuboTV
$34.78 /

+4.66 (+15.47%)

DNMR Danimer Scientific
$38.84 /

+4.49 (+13.07%)

CHNG Change Healthcare
$24.05 /

+ (+0.00%)

Wednesday
Hot Stocks
Align Technology establishes global corporate headquarters in Tempe » 08:32
01/20/21
01/20
08:32
01/20/21
08:32
ALGN

Align Technology

$557.46 /

-10.12 (-1.78%)

Align Technology…

Align Technology announced that it established its new global corporate headquarters in Tempe, Arizona, effective January 1. The company's San Jose campus remains the hub for its global innovation, product, and marketing organization and will become home to its new Digital Innovation Center, currently under construction. As part of the new corporate headquarters move, Align Technology President and CEO Joe Hogan, CFO and Senior Vice President, Global Finance John Morici, Senior Vice President, Chief Legal and Regulatory Officer Julie Coletti, and Senior Vice President, Global HR Stuart Hockridge have relocated their offices to Tempe. Approximately 150 employees, mostly in corporate general and administrative roles, have been offered relocation packages. These employees have the option to relocate to Tempe or to continue working from their current locations. Relocation is not required and there are no layoffs associated with this move.

ShowHide Related Items >><<
ALGN Align Technology
$557.46 /

-10.12 (-1.78%)

ALGN Align Technology
$557.46 /

-10.12 (-1.78%)

01/04/21 Evercore ISI
Align Technology upgraded to Outperform from In Line at Evercore ISI
01/04/21 Evercore ISI
Align Technology upgraded to Outperform from In Line at Evercore ISI
11/24/20 SVB Leerink
Align Technology price target raised to $520 from $460 at SVB Leerink
11/24/20 Credit Suisse
Align Technology price target raised to $515 from $432 at Credit Suisse
ALGN Align Technology
$557.46 /

-10.12 (-1.78%)

ALGN Align Technology
$557.46 /

-10.12 (-1.78%)

ALGN Align Technology
$557.46 /

-10.12 (-1.78%)

Hot Stocks
Progenity reaches 2M test milestone » 07:31
01/20/21
01/20
07:31
01/20/21
07:31
PROG

Progenity

$6.34 /

+0.89 (+16.33%)

Progenity has reported…

Progenity has reported the completion of two million diagnostic tests by its CLIA-certified and CAP-accredited laboratory in Ann Arbor, Michigan. This notable milestone comes as Progenity celebrates the ten-year anniversary of the company's founding.

ShowHide Related Items >><<
PROG Progenity
$6.34 /

+0.89 (+16.33%)

PROG Progenity
$6.34 /

+0.89 (+16.33%)

01/14/21 Piper Sandler
Progenity price target lowered to $10 from $15 at Piper Sandler
12/08/20 Piper Sandler
Progenity shares not trading on fundamentals, says Piper Sandler
11/10/20 Piper Sandler
Progenity price target lowered to $15 from $17 at Piper Sandler
10/29/20 Piper Sandler
Piper Sandler still likes Progenity despite 'spooky' Q3 miss
PROG Progenity
$6.34 /

+0.89 (+16.33%)

  • 03
    Dec
  • 19
    Jun
PROG Progenity
$6.34 /

+0.89 (+16.33%)

PROG Progenity
$6.34 /

+0.89 (+16.33%)

Syndicate
Fulcrum Therapeutics 4M share Spot Secondary priced at $11.00 » 06:07
01/20/21
01/20
06:07
01/20/21
06:07
FULC

Fulcrum Therapeutics

$11.77 /

+0.83 (+7.59%)

SVB Leerink, Piper…

SVB Leerink, Piper Sandler and Credit Suisse acted as joint book running managers for the offering.

ShowHide Related Items >><<
FULC Fulcrum Therapeutics
$11.77 /

+0.83 (+7.59%)

FULC Fulcrum Therapeutics
$11.77 /

+0.83 (+7.59%)

10/15/20 Piper Sandler
Fulcrum Therapeutics initiated with an Overweight at Piper Sandler
08/12/20
Fly Intel: Top five analyst downgrades
08/12/20 BTIG
Fulcrum Therapeutics price target lowered to $22 from $27 at BTIG
08/12/20 Morgan Stanley
Fulcrum Therapeutics downgraded at Morgan Stanley, price target slashed to $11
FULC Fulcrum Therapeutics
$11.77 /

+0.83 (+7.59%)

  • 20
    Jan
FULC Fulcrum Therapeutics
$11.77 /

+0.83 (+7.59%)

Downgrade
ShockWave Medical downgraded to Neutral from Overweight at Piper Sandler » 05:00
01/20/21
01/20
05:00
01/20/21
05:00
SWAV

ShockWave Medical

$142.06 /

+5 (+3.65%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder downgraded ShockWave Medical to Neutral from Overweight with a price target of $132, up from $96. The analyst steps to the sidelines "for the time being due to valuation." Additionally, he believes the resurgence of COVID-19 cases and "fairly high" buy-side expectations make for a "less-than-optimal" setup heading into the Q4 results. Maeder thinks the stock already reflects some upside to numbers and is unsure how much more multiple expansion will materialize over the next 12 months.

ShowHide Related Items >><<
SWAV ShockWave Medical
$142.06 /

+5 (+3.65%)

SWAV ShockWave Medical
$142.06 /

+5 (+3.65%)

01/13/21 Piper Sandler
MCIT finalized rule 'important win' for medical technology, says Piper Sandler
01/12/21 Wells Fargo
ShockWave Medical price target raised to $134 from $95 at Wells Fargo
12/03/20 Piper Sandler
Piper boosts ShockWave Medical target to $96, likes setup into 2021
12/02/20 Oppenheimer
Oppenheimer stays at Perform on ShockWave, highlights paper on IVL-induced VFib
SWAV ShockWave Medical
$142.06 /

+5 (+3.65%)

  • 17
    Jun
Recommendations
Omnicell price target raised to $140 from $125 at Benchmark » 04:57
01/20/21
01/20
04:57
01/20/21
04:57
OMCL

Omnicell

$121.56 /

+0.71 (+0.59%)

Benchmark analyst Bill…

Benchmark analyst Bill Sutherland raised the firm's price target on Omnicell to $140 from $125 and keeps a Buy rating on the shares after the company last week issued a preliminary Q4 beat, increased 2021 guidance and established 2025 growth targets that include five-year annual growth of 50% for its software-as-a-service and technology enabled service offerings. The strong outlook reflects the increased stress on hospital pharmacy management during the pandemic and a greater recognition of Omnicell's automated pharmacy benefits, Sutherland tells investors in a research note.

ShowHide Related Items >><<
OMCL Omnicell
$121.56 /

+0.71 (+0.59%)

OMCL Omnicell
$121.56 /

+0.71 (+0.59%)

01/14/21 Craig-Hallum
Omnicell price target raised to $142 from $100 at Craig-Hallum
12/09/20 Piper Sandler
Pontential Baxter, Omnicell deal makes sense, says Piper Sandler
12/09/20 Benchmark
Omnicell price target raised to $125 from $100 at Benchmark
12/08/20 Berenberg
Berenberg starts four healthcare technology companies with Buy ratings
OMCL Omnicell
$121.56 /

+0.71 (+0.59%)

OMCL Omnicell
$121.56 /

+0.71 (+0.59%)

OMCL Omnicell
$121.56 /

+0.71 (+0.59%)

Tuesday
Hot Stocks
Inspire appoints Bryan Phillips as chief compliance officer, general counsel » 16:08
01/19/21
01/19
16:08
01/19/21
16:08
INSP

Inspire Medical

$224.07 /

+14.13 (+6.73%)

, CERE

Cerevel Therapeutics

$14.51 /

+0.095 (+0.66%)

Inspire Medical (INSP)…

Inspire Medical (INSP) announced the appointment of Bryan Phillips as senior VP, general counsel, chief compliance officer and corporate secretary. Phillips is a legal executive with broad corporate experience in the healthcare industry.Most recently, Phillips served as chief legal officer at Cerevel Therapeutics (CERE).

ShowHide Related Items >><<
INSP Inspire Medical
$224.07 /

+14.13 (+6.73%)

CERE Cerevel Therapeutics
$14.51 /

+0.095 (+0.66%)

INSP Inspire Medical
$224.07 /

+14.13 (+6.73%)

01/07/21 Lake Street
Inspire Medical price target raised to $215 from $150 at Lake Street
01/04/21 BofA
Inspire Medical downgraded to Neutral from Buy at BofA
12/15/20 Goldman Sachs
Inspire Medical downgraded to Neutral from Buy at Goldman Sachs
12/03/20 Piper Sandler
Inspire Medical price target raised to $210 from $147 at Piper Sandler
CERE Cerevel Therapeutics
$14.51 /

+0.095 (+0.66%)

12/10/20 Goldman Sachs
Cerevel Therapeutics initiated with a Buy at Goldman Sachs
11/23/20 Jefferies
Cerevel Therapeutics initiated with a Buy at Jefferies
11/09/20
Fly Intel: Top five analyst initiations
11/09/20 Stifel
Cerevel Therapeutics initiated with a Buy at Stifel
INSP Inspire Medical
$224.07 /

+14.13 (+6.73%)

  • 14
    Apr
INSP Inspire Medical
$224.07 /

+14.13 (+6.73%)

CERE Cerevel Therapeutics
$14.51 /

+0.095 (+0.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.